Role of bradykinin in preconditioning and protection of the ischaemic myocardium

British Journal of Pharmacology

Volumn 135, Issue 4, 2002, Pages 843-854

  Baxter, G F ^a   Ebrahim, Z ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Bradykinin; Infarction; Ischaemia reperfusion; Ischaemic preconditioning; Neutral endopeptidase

Indexed keywords

8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE TRIPHOSPHATE; AMINOPEPTIDASE P; APSTATIN; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OMAPATRILAT; OPIATE; PERINDOPRILAT; POTASSIUM CHANNEL; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TIOPRONIN; UNCLASSIFIED DRUG; Z 13752A;

CORONARY ARTERY DISEASE; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

EID: 0036188590     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704548     Document Type: Review

References (115)

1. The release of kininase from rat isolated hearts during myocardial ischaemia
2. Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts
3. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657
4. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: Evidence of A3 receptor involvement
5. Vasopeptidase inhibition: A new direction in cardiovascular treatment
6. Oxygen radicals released during ischemic preconditioning contribute to cardio-protection in the rabbit myocardium
7. Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning
8. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning
9. Ramiprilat increases bradykinin outflow from isolated hearts of rat
10. Delayed preconditioning of myocardium: Current perspectives
11. Adenosine receptor involvement in a delayed phase of myocardial protection 24 h after ischaemic preconditioning
12. Bioregulation of kinins: Kallikreins, kininogens and kininases
13. Protective effect of ACE inhibitors on ischaemia-reperfusion-induced arrythmias in rats: Is this effect related to the free radical scavenging action of these drugs
14. The kallikrein-kininogen-kinin system: Lessons from quantification of endogenous kinins
15. The late phase of preconditioning
16. Role of kinins in the endothelial protective effects of ischaemic preconditioning
17. Evidence that prostaglandins I2, E2 and D2 may activate ATP sensitive potassium channels in the isolated rat heart
18. Role of bradykinin in cardiac functional protection after global ischaemia-reperfusion in rat heart
19. Angiotensin-converting enzyme inhibitors
20. Bradykinin protects against infarction but does not mediate ischaemic preconditioning in the isolated rat heart
21. Kinins in pain and inflammation
22. Towards understanding the kallikrein-kinin system: Insights from measurement of kinin peptides
23. 1 receptor
24. Ischaemic preconditioning: From adenosine receptor to KATP channel
25. 2 receptor stimulation is calcium-independent
26. Beneficial effect of captopril against ischaemia-reperfusion injury in isolated guinea pig hearts
27. Type-B natriuretic peptide limits infarct size in rat isolated heart
28. Metabolism of bradykinin by the rat coronary vascular bed
29. Bradykinin-induced cardioprotection is attenuated in the hypertrophied rat heart
30. 2 receptor
31. Bradykinin elicits 'second window' myocardial protection in rat heart through an NO-dependent mechanism
32. Metabolism of bradykinin by peptidases in health and disease
33. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor
34. Cardioprotective effects of the aminopeptidase P inhibitor apstatin: Studies on ischaemia/reperfusion injury in the isolated rat heart
35. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation
36. Bradykinin pretreatment improves ischaemia tolerance of the rabbit heart by tyrosine mediated pathways
37. Bradykinin protects the rabbit heart after cardioplegic ischaemia via NO-dependent pathways
38. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase
39. ATP channnels
40. Coronary blood flow and myocardial ischemia
41. Role of bradykinin in protection of ischaemic preconditioning in rabbit hearts
42. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischaemic injury and does not prevent early preconditioning
43. Bradykinin receptors: Pharmacological properties and biological roles
44. Bradykinin receptors
45. Coronary endothelial dysfunction increases the severity of ischaemia-induced ventricular arrhythmias in rat isolated perfused hearts
46. Bradykinin and cardioprotection: Don't set your heart on it
47. Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin
48. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
49. Endothelial function and bradykinin in humans
50. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
51. ACE inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium
52. Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: Involvement of bradykinin, protein kinase C and prostaglandins
53. Adenosine A3 agonist cardioportection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX
54. Infarct size limitation by bradykinin receptor activation is mediated by mitochondrial but not the sarcolemmal K (ATP) channel
55. Kallidin- and bradykinin-degrading pathways in human heart
56. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart
57. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxyepeptidase N in human plasma
58. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia
59. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty
60. Role of kinins in the pathophysiology of myocardial ischaemia. In vitro and in vivo studies
61. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart
62. t adenosine receptors in rabbit heart
63. Endothelial nitric oxide synthase interactions with G-protein coupled receptors
64. Bradykinin accounts for improved postischaemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat
65. Cardioprotective effect of angiotensin converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat myocytes
66. Adrenergic induction of bimodal myocardial protection: Signal transduction and cardiac gene reprogramming
67. 2 receptor activation
68. Characterisation of bradykinin B, receptors in adult myocardium and neonatal rat cardiomyocytes
69. Capase inhibition and limitation of myocardial infarct size: Protection against lethal reperfusion injury
70. 2+ dynamics in endothelial cells
71. 2 receptor activation in human heart
72. Preconditioning with ischaemia: A delay of lethal cell injury in ischaemic myocardium
73. ATP channels in preconditioning
74. Enzymatic inactivation of major circulating forms of arterial and brain natriuretic peptide
75. Cardiac interstitial bradykinin release during ischaemia is enhanced by ischaemic preconditioning
76. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning
77. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects
78. Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation
79. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin
80. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs
81. S6K
82. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin converting enzyme and neutral endopeptidase
83. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin
84. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide
85. Role of mitochondrial and sarcolemmal K(ATP) channels in ischaemic preconditioning of the canine heart
86. Myocardial injury and repair
87. Bradykinin-mediated metabolic effects in isolated perfused rat hearts
88. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist
89. Opioids and cardioprotection
90. Ischaemic preconditioning in pigs: A graded phenomenon
91. Endopeptidase inhibitors decrease myocardial ischaemia/reperfusion injury in an in vivo rabbit model
92. Preischaemic bradykinin and ischaemic preconditioning in functional recovery of globally ischaemic rat heart
93. α-Human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs
94. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction
95. Beneficial effects of bradykinin on porcine ischaemic myocardium
96. In vivo effect of bradykinin during ischaemia and reperfusion: Improved electrical stability two weeks after myocardial infarction in the pig
97. Pretreatment with the adenosine A1 selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits
98. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo
99. Vasopeptidase inhibition in heart failure
100. Cardioprotection from ischaemic preconditioning is lost following prolonged reperfusion in the rabbit
101. 2 receptors
102. Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs
103. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetised dogs
104. Role of bradykinin in myocardial preconditioning
105. Emerging treatments For hypertension: Potential role for vasopeptidase inhibition
106. 1-receptor antagonism
107. Kinins and cardioprotection
108. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway
109. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: The role of kinins
110. 2 receptor knockout mice and kininogen-deficient rats
111. Endothelial nitric oxide gene knockout mice. Cardiac phenotypes and effect of angiotensin-converting enzyme inhibitor on myocardial ischaemia/reperfusion injury
112. Reperfusion injury revisited: Is there a role for growth factor signaling in limiting lethal reperfusion injury?
113. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischaemia and reperfusion
114. Bradykinin improves postischaemic recovery in the rat heart: Role of high energy phosphates, nitric oxide and prostacyclin
115. Inhibiting tissue angiotensin-converting enzyme, a pound of flesh without the blood